PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
6.84%
Net income growth under 50% of CRK's 32.08%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
9.05%
D&A growth well above CRK's 3.71%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-697.22%
Negative yoy deferred tax while CRK stands at 26.61%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
1315.77%
Well above CRK's 66.31% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1315.77%
Growth of 1315.77% while CRK is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
128.43%
Well above CRK's 155.44%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-3.02%
Negative yoy CFO while CRK is 24.75%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-165.51%
Both yoy lines negative, with CRK at -112.27%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-59.93%
We reduce yoy other investing while CRK is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-189.76%
Both yoy lines negative, with CRK at -114.03%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
100.00%
Debt repayment growth of 100.00% while CRK is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
230.06%
Lower share issuance yoy vs. CRK's 713.20%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
100.86%
Buyback growth of 100.86% while CRK is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.